Материал: КР+НПВС+2018-1

187.Souter A. Controversies in the perioperative use of nonsteroidal anti-inflammatory drugs. Anesth Analg. 1994 Dec;79(6):1178-90. doi: 10.1213/00000539-199412000-00025

188.Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and the risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA. 1996 Feb 7;275(5):376-82.

doi: 10.1001/jama.1996.03530290046036

189.Weber EW, Slappendel R, Durieux ME, et al. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiol. 2003 Dec;20(12):963-6.

doi: 10.1097/00003643-200312000-00005

190.Bricker SR, Savage ME, Hanning CD. Perioperative blood loss and non-steroidal anti-inflammatory drugs: an investigation using diclofenac in patients undergoing transurethral resection of the prostate. Eur J Anaesthesiol. 1987 Nov;4(6):429-34.

191.Wierod FS, Frandsen NJ, Jacobsen JD, et al. Risk of haemorrhage from transurethral prostatectomy in acetylsalicylic acid and NSAID-treated patients. Scand J Urol Nephrol. 1998 Apr;32(2): 120-2. doi: 10.1080/003655998750014495

192.Nikanne E, Kokki H, Salo J, Linna TJ. Celecoxib and ketoprofen for pain management during tonsillectomy: a placebo-controlled clinical trial. Otolaryngol Head Neck Surg. 2005 Feb;132(2):28794. doi: 10.1016/j.otohns.2004.09.005

193.Moiniche S, Romsing J, Dahl JB, Tramrr MR. Nonsteroidal antiinflammatory drugs and the risk of operative site bleeding after tonsillectomy: A quantitative systematic review. Anesth Analg. 2003 Jan;96(1):68-77. doi: 10.1213/00000539-200301000-00015

194.Forrest JB, Camu F, Greer IA, et al. Ketorolac, diclofenac, and ketoprofen are equally safe for pain re-lief after major surgery. Br J Anaesth. 2002 Feb;88(2):227-33. doi: 10.1093/bja/88.2.227

195.Deutsch D, Boustiere C, Ferrari E, et al. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therap Adv Gastroenterol. 2017 Jun;10(6):495-505. doi: 10.1177/1756283X17702092. Epub 2017 Apr 17.

196.Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol. 2017 Mar 21;23(11):1954-63. doi: 10.3748/ wjg.v23.i11.1954

197.Мороз ЕВ, Каратеев АЕ, Крюков ЕВ, Чернецов ВА. Желу- дочно-кишечные кровотечения при использовании новых пероральных антикоагулянтов: эпидемиология, факторы риска, лечение и профилактика. Научно-практическая ревматология. 2017;55(6):675-84 [Moroz EV, Karateev AE,

Kryukov EV, Chernetsov VA. Gastrointestinal bleeding with the use of new oral anticoagulants: epidemiology, risk factors, treatment, and prevention. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):675-684

(In Russ.)]. doi: 10.14412/1995-4484-2017-675-684

198.Elia N, Lysakowski C, Tramer MR. Does Multimodal Analgesia with Acetaminophen, Non-steroidal Antiinflammatory Drugs, or Selective Cyclooxygenase-2 Inhibitors and Patient-controlled Analgesia Morphine Offer Advantages over Morphine Alone?: Meta-analyses of Randomized Trials. Anesthesiology. 2005 Dec;103(6):1296-304. doi: 10.1097/00000542-200512000-00025

199.Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory druginduced hepatoxicity. Clin Liver Dis. 2013 Nov;17(4):643-56, ix. doi: 10.1016/j.cld.2013.07.009. Epub 2013 Sep 4.

200.Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol. 2010 Dec 7;16(45):5651-61. doi: 10.3748/wjg.v16.i45.5651

201.Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009 Feb;104(2):356-62. doi: 10.1038/ajg.2008.149. Epub 2009 Jan 27.

202.Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in patient treated with COX-2 selective inhibitors or nonselective NSAIDs: A case/noncase analysis of

spontaneous reports. Clin Ther. 2006 Aug;28(8):1123-32. doi: 10.1016/j.clinthera.2006.08.014

203.Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal antiinflammatory drugs. BMJ. 2003 Jul 5;327(7405):18-22.

doi: 10.1136/bmj.327.7405.18

204.Donati M, Conforti A, Lenti MC, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol. 2016 Jul;82(1):238-48. doi: 10.1111/bcp.12938. Epub 2016 Apr 27.

205.Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013 Feb;36(2):135-44. doi: 10.1007/s40264-012-0013-7

206.Каратеев АЕ. Российский опыт применения нимесулида: обзор клинических испытаний. Consilium medicum. 2011; 13(9):89-95 [Karateev AE. Russian experience of nimesulide: review of clinical trials. Consilium medicum. 2011;13(9):

89-95 (In Russ.)].

207.Каратеев АЕ, Журавлева МВ. Анализ спонтанных сообщений российских врачей о неблагоприятных реакциях, возникших на фоне приема нимесулида: гепатотоксические осложнения очень редки. Эффективная фармакотерапия. 2015;(8):4-12 [Karateev AE, Zhuravleva MV. Analysis of spontaneous Russian doctors about the adverse reactions that occurred in patients receiving nimesulide: hepatotoxic complications are very rare. Effektivnaya Farmakoterapiya. 2015;(8):4-12 (In Russ.)].

208.Andres E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol. 2008 Jan;15(1):15-21. doi: 10.1097/MOH.0b013e3282f15fb9

209.Hamerschlak N, Cavalcanti AB. Neutropenia, agranulocytosis and dipyrone. Sao Paulo Med J. 2005 Sep 1;123(5):247-9. doi: 10.1590/S1516-31802005000500009 Epub 2005 Dec 8.

210.Mourad AA, Bahna S. Hypersensitivities to non-steroidal antiinflammatory drugs. Expert Rev Clin Immunol. 2014 Sep;10(9): 1263-8. doi: 10.1586/1744666X.2014.946905. Epub 2014 Aug 4.

211.Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013 Oct;68(10):1219-32. doi: 10.1111/all.12260. Epub 2013 Oct 5.

212.White AA, Stevenson DD. Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. Semin Respir Crit Care Med. 2012 Dec;33(6):588-94. doi: 10.1055/s-0032- 1325618. Epub 2012 Oct 9.

213.Simon RA. Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. doi: 10.1007/s11882-004-0037-x

214.Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15 Suppl 3:S2. doi: 10.1186/ar4174. Epub 2013 Jul 24.

215.Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140- 6736(13)60900-9. Epub 2013 May 30.

216.Chinese Rheumatism Data Center; Chinese Systemic Lupus Erythematosus Treatment and Research Group. Recommendation for the prevention and treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications. Zhonghua Nei Ke Za Zhi. 2017 Jan 1;56(1):81-5. doi: 10.3760/cma.j.issn.0578-1426.2017.01.021

217.Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011 May;70(5):818-22. doi: 10.1136/ard.2010. 128660. Epub 2010 Sep 10.

218.Singh G, Triadafilopoulos S. Appropriative choice of proton pump inhibitor therapy in the prevention and management of

NSAID-related gastrointestinal damage. Int J Clin Pract. 2005 Oct;59(10):1210-7. doi: 10.1111/j.1368-5031.2005.00660.x

219.Lanas A, Tornero J, Zamorano JL. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis. 2010 Aug;69(8):

1453-8. doi: 10.1136/ard.2009.123166. Epub 2010 May 24.

220.Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl- 2016-312288. Epub 2016 Oct 5.

221.Huang J, Sridhar S, Hunt R. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14-22. doi: 10.1016/ S0140-6736(02)07273-2

222.Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users. Am J Gastroenterol. 2015 May;110(5):684-9. doi: 10.1038/ajg.2015.98. Epub 2015 Apr 21.

223.Conroy RM, Pyorala K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):9871003. doi: 10.1016/S0195-668X(03)00114-3

224.Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016 Jul;23(11):NP1-NP96. doi: 10.1177/2047487316653709. Epub 2016 Jun 27.

225.Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3.

226.Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013 Jan 8;15(1):R6. doi: 10.1186/ar4134

227.Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010 Jul 17; 376(9736):173-9. doi: 10.1016/S0140-6736(10)60673-3. Epub 2010 Jun 16.

228.Chan FKL, Ching JYL, Tse YK, et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN):

an industry-independent, double-blind, double-dummy, randomised trial. Lancet. 2017 Jun 17;389(10087):2375-82. doi: 10.1016/S0140-6736(17)30981-9. Epub 2017 Apr 11.

229.Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/ 11633470-000000000-00000

230.Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A metaanalysis. PLoS One. 2018 Jan 10;13(1):e0190798. doi: 10.1371/ journal.pone.0190798. eCollection 2018.

231.Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007 Feb 10;369(9560):465-73. doi: 10.1016/S0140-6736(07)60234-7

232.Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective

inhibitor etoricoxib and the traditional nonsteroidal anti-inflam- matory drug diclofenac. Gastroenterology. 2008 Nov;135(5):1517-

25. doi: 10.1053/j.gastro.2008.07.067. Epub 2008 Aug 3.

233.Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med. 1999;107:48-54. doi: 10.1016/S0002-9343(99) 00367-8

234.Yang M, Wang HT, Zhao M, et al. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury. Medicine (Baltimore). 2015 Oct;94(40):e1592. doi: 10.1097/MD. 0000000000001592

235.Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular tromboembolic complications with meloxicam. Am J Med. 2004 Jul 15;117(2):100-6.

doi: 10.1016/j.amjmed.2004.03.012

236.Castellsague J, Pisa F, Rosolen V, et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf. 2013 Apr;22(4):365-75.

doi: 10.1002/pds.3385

237.Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78. doi: 10.2165/00003495-200161090-00012

238.Каратеев АЕ, Цурган АВ. Ацеклофенак: опыт российских исследований. Современная ревматология. 2017;11(4):89-94 [Karateev AE, Tsurgan AV. Aceclofenac: the experience of Russian studies. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017;11(4):89-94 (In Russ.)].

doi: 10.14412/1996-7012-2017-4-89-94

239.Walker C, Biasucci LM. Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. Postgrad Med. 2018 Jan; 130(1):55-71. doi: 10.1080/00325481.2018.1412799.

Epub 2017 Dec 15.

240.Tacconelli S, Bruno A, Grande R, et al. Nonsteroidal antiinflammatory drugs and cardiovascular safety – translating pharmacological data into clinical readouts. Expert Opin Drug Saf. 2017 Jul;16(7):791-807. doi: 10.1080/14740338.2017.1338272. Epub 2017 Jun 8.

241.Antman EM. Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs. Circulation. 2017 May 23;135(21):2062-72. doi: 10.1161/CIRCULATIONAHA.117. 027288

242.Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086

243.Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflamma- tory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Safety. 2013;22:559-70. doi.org/10.1002/pds.3437

244.Eisner F, Hermann D, Bajaeifer K, et al. Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience. Visc Med. 2017 Jun;33(3):221-6. doi: 10.1159/000475450. Epub 2017 Jun 16.

245.Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017 Mar;152(4):706-15.

doi: 10.1053/j.gastro.2017.01.031

246.Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017 Jan 15;11(1):27-37. doi: 10.5009/gnl15502

247.Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016 Nov 9;14(1):179. doi: 10.1186/s12916-016-0718-z

248.Gargallo CJ, Sostres C, Lanas A. Prevention and Treatment of NSAID Gastropathy. Curr Treat Options Gastroenterol. 2014 Dec; 12(4):398-413. doi: 10.1007/s11938-014-0029-4

249.Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S5. doi: 10.1186/ar4177. Epub 2013 Jul 24.

250.Yang M, He M, Zhao M, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017 Jun;33(6):973-80. doi: 10.1080/03007995.2017.1281110. Epub 2017 Jan 25.

251.Spiegel BM, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med. 2006 May;119(5):448.e27-36. doi: 10.1016/j.amjmed.2005.11.020

252.Каратеев АЕ. Шесть ножей в спину ингибиторам протонной помпы. Научно-практическая ревматология. 2013;51(3):33240 [Karateev AE. Six stabs in the back of proton pump inhibitors.

Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):332-40 (In Russ.)]. doi: 10.14412/1995- 4484-2013-1509

253.Maes ML, Fixen DR, Linnebur SA. Adverse effects of protonpump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017 Sep;8(9):273-97. doi: 10.1177/20420986 17715381. Epub 2017 Jun 29.

254.Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):697-710. doi: 10.1038/ nrgastro.2017.117. Epub 2017 Sep 20.

255.Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014 Apr; 37(4):201-11. doi: 10.1007/s40264-014-0144-0

256.Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. doi: 10.1038/clpt.2010.219

257.Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012 Sep;40(9):1698-711. doi: 10.1124/dmd.112.045575. Epub 2012 May 30.

258.Ohbuchi M, Noguchi K, Kawamura A, Usui T. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica. 2012 Jul;42(7):633-40. doi: 10.3109/ 00498254.2011.653655. Epub 2012 Feb 7.

259.Neubauer H, Engelhardt A, Krü ger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel – a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol. 2010 Jul;56(1):91-7. doi: 10.1097/FJC.0b013e3181e19739

260.Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9): 937-44. doi: 10.1001/jama.2009.261

261.Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-8. doi: 10.1503/cmaj.082001

262.Johnson DA, Chilton R, Liker HR. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling. Postgrad Med. 2014 May;126(3):239-45. doi: 10.3810/pgm.2014. 05.2772

263.Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcer by esomeprazole in at-risk patients using non-selective NSAIDs or COX-2 inhibitor. Am J Gastroenterol. 2006 Apr;101(4):701-10. doi: 10.1111/j.1572-0241.2006.00499.x Epub 2006 Feb 22.

264.Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxy- genase-2 inhibitor and a pro-ton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a doubleblind, randomised trial. Lancet. 2007 May 12;369(9573):1621-6. doi: 10.1016/S0140-6736(07)60749-1

265.Tang CL, Ye F, Liu W, et al. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients

using nonsteroidal anti-inflammatory drugs: a meta-analysis. Helicobacter. 2012;17:286-96. doi: 10.1111/j.1523-5378.2012.00942.x

266.Ивашкин ВТ, Маев ИВ, Лапина ТЛ и др. Лечение инфекции Helicobacter pylori: мейнстрим и новации (Обзор литературы и резолюция Экспертного совета Российской гастроэнтерологической ассоциации 19 мая 2017 г.). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(4):4-21 [Ivashkin VT, Maev IV, Lapina TL, et al. Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and the resolution of the Expert Council of the Russian Gastroenterological Association on May 19, 2017). Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2017;27(4):4-21 (In Russ.)].

267.Tai FWD, McAlindon ME. NSAIDs and the small bowel. Curr Opin Gastroenterol. 2018 May;34(3):175-82. doi: 10.1097/MOG. 0000000000000427

268.Washio E, Esaki M, Maehata Y, et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory DrugInduced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2016 Jun;14(6):809-15.e1.

doi: 10.1016/j.cgh.2015.10.022. Epub 2015 Oct 30.

269.Syer SD, Blackler RW, Martin R, et al. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol. 2015 Apr; 50(4):387-93. doi: 10.1007/s00535-014-1032-1. Epub 2015 Jan 10.

270.Lee JH, Lee YC, Jeon SW, et al. Guidelines of prevention and treatment for NSAID-related peptic ulcers. Korean J Gastroenterol. 2009;54:309-17. doi: 10.4166/kjg.2009.54.5.309

271.Iijima K, Ichikawa T, Okada S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci. 2009;54:1500-7.

doi: 10.1007/s10620-008-0507-4

272.Мороз ЕВ, Каратеев АЕ. Ребамипид: эффективная медикаментозная профилактика НПВП-энтеропатии возможна. Современная ревматология. 2016;10(4):97-105 [Moroz EV, Karateev AE. Rebamipide: Effective drug prevention of NSAID enteropathy is possible. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(4):97-105 (In Russ.)].

doi: 10.14412/1996-7012-2016-4-97-105

273.Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2017 Dec 1. doi: 10.1007/s10620-017- 4871-9 [Epub ahead of print].

274.Hasegawa M, Horiki N, Tanaka K, et al. The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Mod Rheumatol. 2013 Nov;23(6):1172-8.

doi: 10.1007/s10165-012-0819-2. Epub 2013 Jan 10.

275.Park SH, Cho CS, Lee OY, et al. Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled TrialSTORM STUDY. J Clin Biochem Nutr. 2007 Mar;40(2):148-55. doi: 10.3164/jcbn.40.148

276.Kim JH, Park SH, Cho CS, et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver. 2014 Jul;8(4):371-9. doi: 10.5009/gnl. 2014.8.4.371. Epub 2013 Dec 24.

277.Kurokawa S, Katsuki S, Fujita T, et al. A randomized, doubleblinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2014 Feb;49(2):239-44. doi: 10.1007/s00535-013-0805-2. Epub 2013 Apr 18.

278.Watanabe T, Takeuchi T, Handa O, et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to- severe small intestinal damage. PLoS One. 2015 Apr 15;10(4): e0122330. doi: 10.1371/journal.pone.0122330. eCollection 2015.

279.Zhang S, Qing Q, Bai Y, et al. Rebamipide helps defend against

nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013 Jul;58(7):1991-2000. doi: 10.1007/s10620-013-2606-0. Epub 2013 Feb 28.

280.Yokoyama H, Ito N, Soeda S, et al. Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of aspirin. J Clin Pharm Ther. 2013 Feb;38(1):12-5. doi: 10.1111/j.1365-2710.2012. 01373.x. Epub 2012 Aug 6.

281.Hohlfeld T, Saxena A, Schrör K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs – pharmacological mechanisms and clinical relevance. Thromb Haemost. 2013 May;109(5):825-33. doi: 10.1160/TH12-07-0532. Epub 2012 Dec 13.

282.Meek IL, Vonkeman HE, Kasemier J, et al. Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol. 2013 Mar;69(3):365-71. doi: 10.1007/s00228-012-1370-y. Epub 2012 Aug 14.

283.Strand V. Are COX-2 inhibitors preferable to non-selective nonsteroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007 Dec 22;370(9605):2138-51. doi: 10.1016/S0140-6736(07)61909-6

284.Группа экспертов под председательством С.А. Бойцова и Н.В. Погосова. Российское кардиологическое общество. Национальное общество профилактической кардиологии. Российское общество профилактики неинфекционных заболеваний. Кардиоваскулярная профилактика 2017. Доступно по ссылке: http://ropniz.ru/wp-content/uploads/2017/11/CVP_2017. pdf [A panel of experts chaired by S.A. Boytsov and N.V. Pogosov. Russian Cardiology Society. National Society of Preventive Cardiology. Russian Society for the Prevention of Noncommunicable Diseases. Cardiovascular prevention 2017. Available from: http://ropniz.ru/wp-content/uploads/2017/ 11/CVP_2017.pdf].

285.Carey RM, Whelton PK; 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults:

Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med. 2018 Mar 6;168(5):351-8. doi: 10.7326/M17-3203. Epub 2018 Jan 23.

286.Рабочая группа членов Правления Научного общества нефрологов России под руководством А.В. Смирнова. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Санкт-Петербург: Левша; 2012. 51 с. [Working group of members of the Board of the Scientific Society of Nephrologists of Russia under the guidance of A.V. Smirnova. National recommendations. Chronic kidney disease: the basic principles of screening, diagnosis, prevention, and approaches to treatment. St. Petersburg: Levsha; 2012. 51 p.]. ISBN 978-5- 93356-129-3

287.Рабочая группа под руководством Денисова И.Н. Общероссийская общественная организация «Ассоциация врачей общей практики (семейных врачей) Российской Федерации» Хроническая болезнь почек. Клинические рекомендации. Москва; 2014. Доступно по ссылке: http://sevgb6.ru/doc/ klinicheskie-rekomendacii/hbp.pdf [The working group, led by Denisov I.N. All-Russian Public Organization «Association of General Practitioners (Family Physicians) of the Russian Federation» Chronic kidney disease. Clinical recommendations. Moscow; 2014. Available from: http://sevgb6.ru/doc/klinicheskierekomendacii/hbp.pdf].

288.Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013 Jun 4; 158(11):825-30. doi: 10.7326/0003-4819-158-11-201306040- 00007

289.National Institute for Health and Care Excelence (NICE): Chronic kidney disease in adults: assessment and management. Available at: https://www.nice.org.uk/guidance/cg182 Accessed September 26th 2017.